---
layout: default
title: Pitavastatin
description: "Pitavastatin çš„è€è—¥æ–°ç”¨æ½›åŠ›åˆ†æã€‚æ¨¡å‹é æ¸¬ç­‰ç´š L5ï¼ŒåŒ…å« 10 å€‹é æ¸¬é©æ‡‰ç—‡ã€‚æŸ¥çœ‹ AI é æ¸¬èˆ‡è‡¨åºŠè­‰æ“šå®Œæ•´å ±å‘Šã€‚"
parent: åƒ…æ¨¡å‹é æ¸¬ (L5)
nav_order: 128
evidence_level: L5
indication_count: 10
---

# Pitavastatin

<p style="font-size: 1.25rem; color: #666; margin-bottom: 1.5rem;">
è­‰æ“šç­‰ç´š: <strong>L5</strong> | é æ¸¬é©æ‡‰ç—‡: <strong>10</strong> å€‹
</p>

---

<div id="pharmacist">

## è—¥å¸«è©•ä¼°å ±å‘Š

</div>

# Pitavastatin è—¥å¸«ç­†è¨˜

## ä¸€å¥è©±ç¸½çµ

<p class="key-answer" data-question="Pitavastatin å¯ä»¥ç”¨æ–¼æ²»ç™‚ä»€éº¼æ–°é©æ‡‰ç—‡ï¼Ÿ">
Pitavastatin ç‚º HMG-CoA é‚„åŸé…¶æŠ‘åˆ¶åŠ‘ï¼ŒTxGNN é æ¸¬å°å®¶æ—æ€§é«˜è†½å›ºé†‡è¡€ç—‡ç­‰è„‚è³ªä»£è¬ç–¾ç—…æœ‰ç™‚æ•ˆï¼Œå·²æœ‰è±å¯Œè‡¨åºŠè©¦é©—åŠæ–‡ç»æ”¯æŒï¼Œéƒ¨åˆ†é æ¸¬èˆ‡ç¾æœ‰é©æ‡‰ç—‡é‡ç–Šã€‚
</p>

## å¿«é€Ÿç¸½è¦½

| é …ç›® | å…§å®¹ |
|------|------|
| è—¥å“å­¸å | Pitavastatin (åŒ¹ä¼ä»–æ±€/ç’°ä¸™çƒ¯è„‚æ±€) |
| DrugBank ID | DB08860 |
| åŸæ ¸å‡†é©æ‡‰ç—‡ | åŸç™¼æ€§é«˜è†½å›ºé†‡è¡€ç—‡ã€æ··åˆå‹è¡€è„‚ç•°å¸¸ã€å…’ç«¥å®¶æ—æ€§é«˜è†½å›ºé†‡è¡€ç—‡ |
| TxGNN é æ¸¬æ–°é©æ‡‰ç—‡ | obsolete familial combined hyperlipidemiaã€homozygous familial hypercholesterolemiaã€hyperlipoproteinemiaã€hyperlipidemia, familial combined, LPL relatedã€familial hypercholesterolemiaã€cholesterol-ester transfer protein deficiencyã€hypercholesterolemia, autosomal dominantã€hypercholesterolemia due to cholesterol 7alpha-hydroxylase deficiencyã€HIV infectious diseaseã€neurodevelopmental disorder with ataxic gait, absent speech, and decreased cortical white matter |
| å°ç£è¨±å¯è­‰æ•¸ | 46 å¼µ |
| æœ€é«˜è­‰æ“šç­‰ç´š | L1-L2 (RCT) |

## ç‚ºä»€éº¼é€™å€‹é æ¸¬åˆç†

Pitavastatin ä½œç‚º statin é¡è—¥ç‰©ï¼Œå…¶é æ¸¬çš„æ–°é©æ‡‰ç—‡åœ¨æ©Ÿè½‰ä¸Šå®Œå…¨åˆç†ï¼š

1. **åŒå‹åˆå­å®¶æ—æ€§é«˜è†½å›ºé†‡è¡€ç—‡ (Homozygous FH)**ï¼šPitavastatin æŠ‘åˆ¶ HMG-CoA é‚„åŸé…¶ï¼Œæ¸›å°‘è‚è‡Ÿè†½å›ºé†‡åˆæˆï¼Œæ˜¯ FH çš„ä¸€ç·šæ²»ç™‚é¸æ“‡
2. **é«˜è„‚è›‹ç™½è¡€ç—‡ (Hyperlipoproteinemia)**ï¼šStatin é¡è—¥ç‰©å¯æœ‰æ•ˆé™ä½ LDL-Cï¼Œå°å„é¡é«˜è„‚è›‹ç™½è¡€ç—‡å‡æœ‰ç™‚æ•ˆ
3. **å®¶æ—æ€§é«˜è†½å›ºé†‡è¡€ç—‡**ï¼šå·²æ˜¯å°ç£æ ¸å‡†é©æ‡‰ç—‡çš„ä¸€éƒ¨åˆ†ï¼Œé æ¸¬èˆ‡ç¾æœ‰é©æ‡‰ç—‡é‡ç–Š

## è‡¨åºŠè©¦é©—è­‰æ“š

| é æ¸¬é©æ‡‰ç—‡ | è‡¨åºŠè©¦é©—æ•¸ | ä»£è¡¨æ€§è©¦é©— |
|------------|-----------|-----------|
| é«˜è„‚è›‹ç™½è¡€ç—‡ | 12 | NCT01256476: Phase 4 æ¯”è¼ƒ Pitavastatin 4mg vs Pravastatin 40mg (å®Œæˆ) |
| å®¶æ—æ€§é«˜è†½å›ºé†‡è¡€ç—‡ | 2 | NCT02107898: Alirocumab æ·»åŠ æ–¼ Pitavastatin æ²»ç™‚ HeFH (å®Œæˆ) |
| åŒå‹åˆå­ FH | 0 | ç›´æ¥ç›¸é—œè©¦é©—å°‘ï¼Œä½†ç•°å‹åˆå­ FH æœ‰å¤šé …è©¦é©— |

### ä¸»è¦è‡¨åºŠè©¦é©—

| è©¦é©— ID | æ¨™é¡Œ | Phase | ç‹€æ…‹ | ä¸»è¦ç™¼ç¾ |
|---------|------|-------|------|----------|
| NCT01256476 | Pitavastatin 4mg vs Pravastatin 40mg | Phase 4 | å®Œæˆ | 328 ä¾‹æ‚£è€…ï¼Œæ¯”è¼ƒå…©è—¥é™ LDL-C æ•ˆæœ |
| NCT01386853 | Pitavastatin vs Atorvastatin éåŠ£æ€§è©¦é©— | Phase 3 | å®Œæˆ | å°ç£åŸ·è¡Œï¼Œ200 ä¾‹é«˜é¢¨éšªæ‚£è€… |
| NCT02056847 | Pitavastatin åœ¨ç©ºè…¹è¡€ç³–ç•°å¸¸æ‚£è€… | Phase 4 | å®Œæˆ | 313 ä¾‹ï¼Œè©•ä¼° HbA1c å½±éŸ¿ |

## æ–‡ç»è­‰æ“š

### åŒå‹åˆå­å®¶æ—æ€§é«˜è†½å›ºé†‡è¡€ç—‡
**è­‰æ“šç­‰ç´šï¼šL3 (ç—…ä¾‹å ±å‘Š)**

| PMID | æ¨™é¡Œ | å¹´ä»½ | é‡é»ç™¼ç¾ |
|------|------|------|----------|
| 39532566 | Rapid lipid-lowering response in ARH | 2025 | Pitavastatin åˆä½µ Ezetimibe åœ¨è‡ªé«”éš±æ€§é«˜è†½å›ºé†‡è¡€ç—‡æœ‰å¿«é€Ÿé™è„‚æ•ˆæœ |

### å®¶æ—æ€§é«˜è†½å›ºé†‡è¡€ç—‡ (ç•°å‹åˆå­)
**è­‰æ“šç­‰ç´šï¼šL2 (å¤šå€‹ RCT)**

| PMID | æ¨™é¡Œ | å¹´ä»½ | é‡é»ç™¼ç¾ |
|------|------|------|----------|
| 29187694 | Pitavastatin in children with FH (Japan/Europe) | 2018 | RCT è­‰å¯¦ Pitavastatin åœ¨å…’ç«¥ FH æ‚£è€…å®‰å…¨æœ‰æ•ˆ |
| 25891210 | Pitavastatin in Japanese male children with FH | 2016 | å¤šä¸­å¿ƒ RCTï¼Œè­‰å¯¦ Pitavastatin åœ¨æ—¥æœ¬å…’ç«¥ FH çš„ç™‚æ•ˆèˆ‡å®‰å…¨æ€§ |
| 12048134 | Long-term treatment with pitavastatin in FH | 2002 | 104 é€±é•·æœŸæ²»ç™‚é¡¯ç¤º LDL-C é™ä½ 49% |
| 10955373 | NK-104 in heterozygous FH | 2000 | åŠ‘é‡ä¾è³´æ€§é™ä½ LDL-Cï¼Œ4mg/å¤©å¯é™ 48% |

### é«˜è„‚è›‹ç™½è¡€ç—‡
**è­‰æ“šç­‰ç´šï¼šL2 (å¤šå€‹ RCT)**

| PMID | æ¨™é¡Œ | å¹´ä»½ | é‡é»ç™¼ç¾ |
|------|------|------|----------|
| 23672789 | Pitavastatin vs Atorvastatin (COMPACT-CAD) | 2013 | RCT é¡¯ç¤º Pitavastatin å¢åŠ  HDL-C åŠ Adiponectin æ•ˆæœå„ªæ–¼ Atorvastatin |
| 17957184 | Pitavastatin vs Atorvastatin on CoQ10 | 2008 | Pitavastatin è¼ƒå°‘å½±éŸ¿ CoQ10 æ¿ƒåº¦ |

## å°ç£ä¸Šå¸‚è³‡è¨Š

### ä¸Šå¸‚ç‹€æ…‹
å°ç£å·²æ ¸å‡†ä¸Šå¸‚ï¼Œå…±æœ‰ 46 å¼µè¨±å¯è­‰ï¼Œç›®å‰æœ‰æ•ˆè¨±å¯è­‰è¶…é 20 å¼µã€‚

### ä»£è¡¨æ€§ç”¢å“

| è¨±å¯è­‰å­—è™Ÿ | å•†å“å | åŠ‘å‹ | è¨±å¯è­‰æŒæœ‰è€… | æ•ˆæœŸ |
|------------|--------|------|--------------|------|
| è¡›éƒ¨è—¥è¼¸å­—ç¬¬027002è™Ÿ | åŠ›æ¸…ä¹‹å£æº¶éŒ 2æ¯«å…‹ (LIVALO) | å£æº¶éŒ  | å°ç”°è—¥å“è‚¡ä»½æœ‰é™å…¬å¸ | 2027/01/19 |
| è¡›éƒ¨è—¥è£½å­—ç¬¬059192è™Ÿ | åº‡è„‚æ¸…è†œè¡£éŒ 4æ¯«å…‹ | è†œè¡£éŒ  | ç‘©ç¢©ç”ŸæŠ€é†«è—¥è‚¡ä»½æœ‰é™å…¬å¸ | 2026/05/23 |
| è¡›éƒ¨è—¥è£½å­—ç¬¬060290è™Ÿ | å¥½è„‚å®šè†œè¡£éŒ 4æ¯«å…‹ | è†œè¡£éŒ  | æ°¸ä¿¡è—¥å“å·¥æ¥­è‚¡ä»½æœ‰é™å…¬å¸ | 2029/05/09 |
| è¡›ç½²è—¥è£½å­—ç¬¬057372è™Ÿ | å¿…æŠ‘è„‚è†œè¡£éŒ 2æ¯«å…‹ | è†œè¡£éŒ  | å‹éœ–ç”ŸæŠ€é†«è—¥è‚¡ä»½æœ‰é™å…¬å¸ | 2027/09/26 |
| è¡›éƒ¨è—¥è£½å­—ç¬¬061165è™Ÿ | åŒæŠ‘è„‚è† å›Š2/10æ¯«å…‹ | è† å›ŠåŠ‘ | å‹éœ–ç”ŸæŠ€é†«è—¥è‚¡ä»½æœ‰é™å…¬å¸ | 2027/10/28 |

### æ ¸å‡†é©æ‡‰ç—‡
- åŸç™¼æ€§é«˜è†½å›ºé†‡è¡€ç—‡
- æ··åˆå‹è¡€è„‚ç•°å¸¸
- 10 æ­²ä»¥ä¸Šå…’ç«¥å®¶æ—æ€§é«˜è†½å›ºé†‡è¡€ç—‡

## å®‰å…¨æ€§è€ƒé‡

### è—¥ç‰©äº¤äº’ä½œç”¨

DDInter è³‡æ–™åº«é¡¯ç¤º Pitavastatin èˆ‡å¤šç¨®è—¥ç‰©æœ‰äº¤äº’ä½œç”¨ï¼š

**ä¸­åº¦äº¤äº’ä½œç”¨ (Moderate)**ï¼š
- Eluxadoline
- Naltrexone
- Metronidazole

### æ³¨æ„äº‹é …
1. **è‚Œè‚‰æ¯’æ€§**ï¼šç›£æ¸¬è‚Œè‚‰ç–¼ç—›ã€ç„¡åŠ›ï¼Œå®šæœŸæª¢æ¸¬ CK å€¼
2. **è‚åŠŸèƒ½**ï¼šé–‹å§‹æ²»ç™‚å‰åŠæ²»ç™‚æœŸé–“å®šæœŸç›£æ¸¬è‚åŠŸèƒ½
3. **è—¥ç‰©äº¤äº’ä½œç”¨**ï¼šPitavastatin ä¸»è¦ç¶“ CYP2C9 ä»£è¬ï¼Œèˆ‡ CYP3A4 ç„¡æ˜é¡¯äº¤äº’ä½œç”¨ï¼Œè¼ƒå…¶ä»– statin è—¥ç‰©äº¤äº’ä½œç”¨é¢¨éšªä½
4. **HIV æ‚£è€…**ï¼šå¯ç”¨æ–¼æ¥å—æŠ—ç—…æ¯’æ²»ç™‚çš„ HIV æ‚£è€…ï¼ˆINTREPID è©¦é©—æ”¯æŒï¼‰

### è—¥ç‰©-é£Ÿç‰©äº¤äº’ä½œç”¨ (DFI)

<div class="dfi-source">è³‡æ–™ä¾†æºï¼š<a href="https://ddinter2.scbdd.com/" target="_blank">DDInter 2.0</a></div>

**é…’ç²¾ (alcohol)** ğŸŸ¡ Moderate
- å½±éŸ¿ï¼šConcomitant use of statin medication with substantial quantities of alcohol may increase the risk of hepatic injury.
- å»ºè­°ï¼šPatients should be counseled to avoid substantial quantities of alcohol in combination with statin medications and clinicians should be aware of the increased risk for hepatotoxicity in these patients...


### è—¥ç‰©-ç–¾ç—…æ³¨æ„äº‹é … (DDSI)

<div class="ddsi-source">è³‡æ–™ä¾†æºï¼š<a href="https://ddinter2.scbdd.com/" target="_blank">DDInter 2.0</a>ï¼ˆåŸæ–‡å…§å®¹è«‹åƒé–±è©²ç¶²ç«™ï¼‰</div>

**ç³–å°¿ç—…** ğŸŸ¡ Moderate
- æ‡‰è¬¹æ…ä½¿ç”¨ï¼›éœ€å¯†åˆ‡ç›£æ¸¬ã€‚

**è…è‡Ÿç–¾ç—…** ğŸŸ¡ Moderate
- æ‡‰è¬¹æ…ä½¿ç”¨ï¼›éœ€å¯†åˆ‡ç›£æ¸¬ï¼›å¯èƒ½éœ€é™ä½åŠ‘é‡ã€‚

**è‚è‡Ÿç–¾ç—…** ğŸŸ¢ Minor
- æ­¤æƒ…æ³ä¸‹ç‚ºç¦å¿Œï¼›éœ€å¯†åˆ‡ç›£æ¸¬ã€‚

**Rhabdomyolysis** ğŸŸ¢ Minor
- éœ€å¯†åˆ‡ç›£æ¸¬ã€‚

## çµè«–èˆ‡ä¸‹ä¸€æ­¥

### é æ¸¬åƒ¹å€¼è©•ä¼°

| é æ¸¬é©æ‡‰ç—‡ | è­‰æ“šç­‰ç´š | æ–‡ç»æ”¯æŒ | è‡¨åºŠè©¦é©— | ç¸½è©• |
|------------|----------|----------|----------|------|
| åŒå‹åˆå­ FH | L3 | 2 ç¯‡ | é–“æ¥ | ä¸­åº¦æ”¯æŒ |
| é«˜è„‚è›‹ç™½è¡€ç—‡ | L2 | 15+ ç¯‡ | 12 | å¼·åŠ›æ”¯æŒ |
| å®¶æ—æ€§é«˜è†½å›ºé†‡è¡€ç—‡ | L1-L2 | 18+ ç¯‡ | 2 | å·²ç‚ºæ ¸å‡†é©æ‡‰ç—‡ |

### å»ºè­°
1. **é«˜è„‚è›‹ç™½è¡€ç—‡**åŠ**å®¶æ—æ€§é«˜è†½å›ºé†‡è¡€ç—‡**é æ¸¬èˆ‡ç¾æœ‰é©æ‡‰ç—‡é«˜åº¦é‡ç–Šï¼Œè­‰å¯¦æ¨¡å‹é æ¸¬æº–ç¢º
2. **åŒå‹åˆå­ FH**ï¼šé›–æ–‡ç»æ”¯æŒè¼ƒå°‘ï¼Œä½†åŸºæ–¼ä½œç”¨æ©Ÿè½‰ï¼ŒPitavastatin å¯ä½œç‚ºç¶œåˆæ²»ç™‚æ–¹æ¡ˆçš„ä¸€éƒ¨åˆ†
3. Pitavastatin è¼ƒå…¶ä»– statin è—¥ç‰©äº¤äº’ä½œç”¨é¢¨éšªä½ï¼Œé©åˆå¤šé‡ç”¨è—¥æ‚£è€…

---
*æœ¬ç­†è¨˜ç”± TwTxGNN ç³»çµ±è‡ªå‹•ç”¢ç”Ÿï¼Œåƒ…ä¾›ç ”ç©¶åƒè€ƒï¼Œä¸æ§‹æˆé†«ç™‚å»ºè­°ã€‚*
*ç”¢ç”Ÿæ—¥æœŸï¼š2026-02-11*

---

## ç›¸é—œè—¥ç‰©å ±å‘Š

- [Emedastine]({{ "/drugs/emedastine/" | relative_url }}) - è­‰æ“šç­‰ç´š L5
- [Theophylline]({{ "/drugs/theophylline/" | relative_url }}) - è­‰æ“šç­‰ç´š L5
- [Isoleucine]({{ "/drugs/isoleucine/" | relative_url }}) - è­‰æ“šç­‰ç´š L5
- [Nitrofurantoin]({{ "/drugs/nitrofurantoin/" | relative_url }}) - è­‰æ“šç­‰ç´š L5
- [Inclisiran]({{ "/drugs/inclisiran/" | relative_url }}) - è­‰æ“šç­‰ç´š L5

---

{% include ai-analysis.html %}

{% include social-share.html %}

## å¼•ç”¨æœ¬å ±å‘Š

å¦‚éœ€å¼•ç”¨æœ¬å ±å‘Šï¼Œè«‹ä½¿ç”¨ä»¥ä¸‹æ ¼å¼ï¼š

**APA æ ¼å¼ï¼š**
```
TwTxGNN. (2026). Pitavastatinè€è—¥æ–°ç”¨é©—è­‰å ±å‘Š. https://twtxgnn.yao.care/drugs/pitavastatin/
```

**BibTeX æ ¼å¼ï¼š**
```bibtex
@misc{twtxgnn_pitavastatin,
  title = {Pitavastatinè€è—¥æ–°ç”¨é©—è­‰å ±å‘Š},
  author = {TwTxGNN Team},
  year = {2026},
  url = {https://twtxgnn.yao.care/drugs/pitavastatin/}
}
```

---

<div class="disclaimer">
<strong>å…è²¬è²æ˜</strong><br>
æœ¬å ±å‘Šåƒ…ä¾›å­¸è¡“ç ”ç©¶åƒè€ƒï¼Œ<strong>ä¸æ§‹æˆé†«ç™‚å»ºè­°</strong>ã€‚è—¥ç‰©ä½¿ç”¨è«‹éµå¾ªé†«å¸«æŒ‡ç¤ºï¼Œåˆ‡å‹¿è‡ªè¡Œèª¿æ•´ç”¨è—¥ã€‚ä»»ä½•è€è—¥æ–°ç”¨æ±ºç­–éœ€ç¶“éå®Œæ•´çš„è‡¨åºŠé©—è­‰èˆ‡æ³•è¦å¯©æŸ¥ã€‚
<br><br>
<small>æœ€å¾Œå¯©æ ¸ï¼š2026-02-20 | å¯©æ ¸è€…ï¼šTwTxGNN Research Team</small>
</div>

{% include giscus.html %}
